Google
BCYC — BICYCLE THERAPEUTICS LTD (Healthcare >> Biotechnology)
BCYC FAQ
What is BCYC's ROE?
BICYCLE THERAPEUTICS LTD reports a Return on Equity (ROE) of -39.51%.
What is BCYC's dividend yield?
BICYCLE THERAPEUTICS LTD offers a dividend yield of 0.00%.
What is BCYC's Deepscope Quality Score?
Deepscope rates BCYC's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BCYC?
Deepscope's AI Timing Score for BCYC is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BCYC belong to?
BICYCLE THERAPEUTICS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.05
Price
-0.05
(-1.22%)
Day Change
|
|
|---|
BCYC, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 79 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.05 |
| PBV / Sector |
0.52 / 4.91
GREAT
|
| Earning Per Share | -3.10 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
1.51 M
GREAT
|
| Average 1W Daily Value |
2.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-13 11:13:22 |
| Symbol | BCYC |
| Name | BICYCLE THERAPEUTICS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 50.37 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 286.23 / 9,034.83 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Portway Building, Cambridge, United Kingdom, CB21 6GS
Phone: 44 1223 261 503
Website: https://www.bicycletherapeutics.com
Employees: 288
Sector: Healthcare >> Biotechnology
Description: Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
